The Metabolic Basis of Kidney Cancer
Fig. 6.1 Kidney cancers are a diverse group of malignancies with distinct genetic and molecular alterations and disparate histologic features (Permission granted from Elsevier) (Linehan et al.) Fig. 6.2 The…
Fig. 6.1 Kidney cancers are a diverse group of malignancies with distinct genetic and molecular alterations and disparate histologic features (Permission granted from Elsevier) (Linehan et al.) Fig. 6.2 The…
Fig. 23.1 Novel immune agents targeting immune signaling. MDX-1106 is a monoclonal antibody with affinity for PD-1. Binding of PD-1 on the T-cell surface to PD-L1/2 on the antigen-presenting cell…
Fig. 18.1 Structure of mTOR. The amino terminal contains tandem HEAT repeats and a FAT domain of unclear function. The kinase domain lies on the carboxy terminal of mTOR and…
Author Follow-up (years) Approach Patients Tumor size (cm) Primary effectiveness (%) Secondary effectiveness (%) DFS (5-year %) OS (5-year %) CSS (5-year %) Ma et al. [86] 5 (median) Mix…
Fig. 10.1 Combined analysis of overall survival in the EORTC 30947 and SWOG 8949 trials. Median overall survival is 7.8 months in the observation group (O=interferon monotherapy) versus 13.6 months…
Fig. 9.1 Risk assessment algorithm for a patient with newly diagnosed localized renal cell carcinoma. Assessing risk occurs throughout the continuum of patient care. Risk assessment during initial evaluation requires…
Interferons (INF): interferon-α, interferon-β, interferon-γ Interleukins (IL): interleukin-2, interleukin-12, interleukin-21 Cytokine combination strategies Cytokine combinations Cytokines + cellular therapies (e.g., IL-2 and tumor-infiltrating lymphocytes) Cytokines and chemotherapy or biologics (e.g.,…
General The lungs The bone The brain Solitary or oligometastatic lesions Metachronous metastasis and long disease-free interval of >2 years Complete resection Single organ site Good performance status (Karnofsky, ECOG,…
Fig. 3.1 Control of HIF activity. Steady-state levels of HIFα are controlled by its rate of synthesis and degradation. The former is regulated by the TORC1 complex, which contains the…
Group N Study type Treatment Primary tumor Disease state MD Anderson Cancer Center [9] 50 Prospective Bevacizumab+/– erlotinib Resectable Metastatic with primary in place: 50 University of North Carolina [6]…